| DB ID | MyCo_3119 |
| Title | Detection of (1,3)-β-d-Glucan for the Diagnosis of Invasive Fungal Infection in Liver Transplant Recipients |
| Year | 2017 |
| PMID | 28422065 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Liver Transplant Recipients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The Institutional Review Board (Henri Mondor Hospital in the suburbs of Paris, France) approved the study (2012-12) and the database was declared to the French Data Protection Authority (Commission Nationale Informatique et Liberté) (No. 1699340). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | This study was carried out in liver transplant patients at Henri Mondor Hospital in the suburbs of Paris, France. Between January 2013 and May 2016, all patients admitted consecutively to our Intensive Care Unit (ICU) following LT were enrolled in the study. Demographic and clinical characteristics, investigations for mycological and bacterial infections, and antimicrobial therapies were all recorded prospectively. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
